- Development and Qualification of the PCF SELECT (Specific Evaluation in Liquid Biopsies of Established Prostate Cancer Targets) Plasma DNA Assay
- Impact of Therapy on Modulation of Neuroendocrine-Associated Gene Expression in Patients With High Risk, Localized Prostate Cancer Treated With Neoadjuvant Docetaxel and Androgen Deprivation Therapy
- Early Detection of Neuroendocrine Prostate Cancer Transformation Using Circulatin Genomic Signatures
- Prostate Cancer Clinical Consortium Clinical Research Site: Targeted Therapies
- Genome Sequencing of Outlier Responders to Systemic Cancer Therapies
- Mechanistic Insights Underlying ERG-Induced Taxane Resistance in Castration-Resistant Prostate Cancer
- Targeting and Mechanistic Insights Underlying N-Myc Driven Neuroendocrine Prostate Cancer
- Co-Clinical Trials Using Organoids for Patients with Advanced Prostate Cancer
- High Throughput Genomic Approaches to Improve Management of Neuroendocrine Prostate Cancer
- A Changing Landscape of Advanced Prostate Cancer: Understanding Mechanisms of Resistance to Potent Hormonal Therapies
- Precision Therapy of Advanced Prostate Cancer
- Precision Medicine Sequencing
- Interrogation of Aberrant DNA Repair in Sporadic Prostate Cancer
- Molecular Signatures of Lethal and Indolent Prostate Cancer
- The Molecular Basis of Neuroendocrine Prostate Cancer